FTSE 100 today: Index rises, pound strengthens; Tullow Oil slumps, Hiscox rises
This article summarizes the most significant insider buying and selling activities reported on Tuesday, February 11, 2025, for US stocks.
Top Insider Buys:
Berkshire Hathaway Inc . (NYSE:BRKa) (NYSE:BRK.A), led by Warren E. Buffett, has increased its stake in Occidental Petroleum Corp. (NYSE:OXY) by purchasing 763,017 additional shares. The acquisition, completed on February 7, 2025, was made at a weighted average price of $46.8195 per share, totaling approximately $35.7 million. Following this purchase, Berkshire Hathaway (NYSE:BRKb) now holds 264,941,431 shares of Occidental’s common stock through its subsidiary, National Indemnity Company. Occidental currently trades at a P/E ratio of 11.8x and offers a dividend yield of 1.81%, with a 22% dividend growth in the last twelve months.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw significant insider buying from Venrock Healthcare Capital Partners (WA:CPAP). The investment firm acquired a total of 104,489 shares across three transactions between February 7 and February 11, 2025, at prices ranging from $9.14 to $9.29 per share. The total investment amounted to approximately $967,144. Following these acquisitions, Venrock’s total holdings in KalVista Pharmaceuticals increased to 5,117,285 shares. The company, valued at $458 million, has shown strong momentum with a 9.45% return year-to-date.
Oncocyte Corp (NASDAQ:OCX) reported a notable insider purchase by Chief Financial Officer James Andrea S. On February 7, 2025, Andrea acquired 97,561 shares of Oncocyte common stock at a price of $2.05 per share, totaling approximately $200,000. This purchase was made through a private placement. Following the transaction, Andrea’s direct ownership in Oncocyte stands at 151,231 shares. The company, currently trading at $2.37 with a market cap of $39.6 million, is rated as having WEAK financial health.
Top Insider Sells:
Rumble Inc. (NASDAQ:RUM) saw significant insider selling activity from multiple executives. Robert Arsov, a director, sold 12,350,025 shares at $7.50 per share, totaling approximately $92.6 million. CEO Christopher Pavlovski sold 9,999,283 shares at the same price, bringing in about $74.9 million. Chief Content Officer Ramolo Claudio sold 6,269,731 shares for approximately $47 million, while CFO Brandon Alexandroff sold 8,872,259 shares for about $66.5 million. Director Ryan Milnes also sold 24,978,210 shares, totaling approximately $187.34 million. These sales were part of Rumble’s self-tender offer, which concluded on February 7, 2025. Despite these sales, Rumble’s stock has shown significant volatility, with a 94% surge over the past six months.
Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company’s prospects. While insider purchases may signal confidence in the company’s future, insider sales don’t necessarily indicate a lack of faith, as they can occur for various personal reasons. However, large-scale selling by multiple insiders, as seen in Rumble’s case, may warrant closer attention to the company’s overall health and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.